Poltreg S.A.

PTG.WA

Biotechnology · Healthcare

Price

26.60 PLN

+0.10 (+0.38%)

Market Cap

157.4M PLN

Exchange

Warsaw Stock Exchange

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Share count rising — dilution

+36.5% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 3.4M (2021) → 4.7M (2025)

Winston Score History

The full picture

Poltreg S.A. is a small Polish biotechnology company focused on developing cell-based therapies for autoimmune diseases. Its main work involves regulatory T-cell (Treg) treatments, which are designed to help the immune system stop attacking the body's own tissues. The company targets patients with conditions like type 1 diabetes and transplant rejection, and it operates primarily in the clinical research and development stage.

Poltreg does not yet sell commercial products, which explains its zero gross margin and deeply negative returns on capital. It is funded through grants, partnerships, and capital raises rather than product revenue. The company is based in Poland and is small even by biotech standards, with a market cap around $100 million. Its main competitive asset is its scientific expertise in Treg cell therapy, a niche but growing area of immunology. The key risk is straightforward: the company must successfully advance its therapies through clinical trials and secure regulatory approval before it runs out of funding.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

YoY Growth Rate

Revenue data limited

EPS Growth

-23.9% YoY

YoY Growth Rate

Earnings declining

R&D Spend

0 PLN/ year

Research and development spending

Insider Activity

55.4%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~3 months

9M PLN cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Cash watch

Poltreg S.A. has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

Data not available

Profit after running costs

Operating Margin

N/A

Data not available

Return on the money invested

ROCE

-95.3%

Weak — -95.3% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

-100.0%

Shrinking sales (-100.0% YoY)

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial